tiprankstipranks
Trending News
More News >
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H (HK:0874)
:0874

Guangzhou Baiyunshan Pharmaceutical Holdings Company (0874) AI Stock Analysis

Compare
0 Followers

Top Page

HK

Guangzhou Baiyunshan Pharmaceutical Holdings Company

(OTC:0874)

Rating:66Neutral
Price Target:
Guangzhou Baiyunshan's overall stock score reflects strong financial performance and attractive valuation. The company's sound equity position and effective cash management are significant strengths. However, technical analysis indicates a bearish trend, which may pose short-term challenges. The absence of recent earnings call data or noteworthy corporate events does not influence the current assessment.

Guangzhou Baiyunshan Pharmaceutical Holdings Company (0874) vs. iShares MSCI Hong Kong ETF (EWH)

Guangzhou Baiyunshan Pharmaceutical Holdings Company Business Overview & Revenue Model

Company DescriptionGuangzhou Baiyunshan Pharmaceutical Holdings Company (0874) is a leading pharmaceutical enterprise based in China, specializing in the research, development, production, and distribution of traditional Chinese medicines, chemical pharmaceuticals, and healthcare products. The company operates in several sectors including pharmaceuticals, healthcare, and consumer products, offering a diverse range of products aimed at improving health and wellness.
How the Company Makes MoneyGuangzhou Baiyunshan Pharmaceutical Holdings Company generates revenue primarily through the sale of its pharmaceutical products, including both traditional Chinese medicines and chemical pharmaceuticals. Key revenue streams include the domestic and international distribution of these products to hospitals, pharmacies, and other healthcare providers. The company also earns money through its consumer healthcare product line, which includes a range of over-the-counter drugs and wellness products. Significant partnerships with healthcare institutions and government agencies, along with a strong distribution network, contribute to its earnings by expanding market reach and enhancing product accessibility.

Guangzhou Baiyunshan Pharmaceutical Holdings Company Financial Statement Overview

Summary
Guangzhou Baiyunshan shows strong financial performance with stable profitability and operational efficiency. The income statement highlights healthy EBIT and EBITDA margins, although revenue growth has slowed slightly. The balance sheet is robust with a strong equity position and moderate leverage, while cash flow demonstrates effective management despite recent fluctuations.
Income Statement
78
Positive
The income statement shows stable profitability with a gross profit margin of approximately 16.7% and a net profit margin of 3.8% for 2024. However, there is a decline in revenue growth from 2023 to 2024, down by 0.7%. EBIT and EBITDA margins are healthy, indicating efficient operations. The company has seen consistent revenue growth over the past years, albeit with a recent slowdown.
Balance Sheet
82
Very Positive
The balance sheet reflects a strong equity position with an equity ratio of 43.9% in 2024. The debt-to-equity ratio is moderate at 0.34, suggesting a balanced approach to leveraging. Return on Equity (ROE) is reasonable at 7.9%, indicating satisfactory profitability from shareholder investments. The company maintains a healthy asset base, providing stability.
Cash Flow
70
Positive
Cash flow analysis reveals a robust operating cash flow to net income ratio of 1.21 for 2024, signifying strong cash generation. The free cash flow to net income ratio is 0.82, reflecting effective cash management despite fluctuations. Free cash flow shows a decline from 2023 due to decreased operating cash flow, indicating potential short-term liquidity concerns.
Breakdown
TTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
74.52B74.99B75.52B70.79B69.01B61.67B
Gross Profit
12.05B12.52B14.19B13.28B13.23B10.44B
EBIT
3.78B3.60B5.12B5.07B4.79B3.67B
EBITDA
4.10B4.90B6.49B5.00B5.82B4.68B
Net Income Common Stockholders
3.02B2.84B4.06B3.97B3.72B2.92B
Balance SheetCash, Cash Equivalents and Short-Term Investments
18.47B18.27B21.31B22.56B22.38B19.47B
Total Assets
56.89B81.68B78.59B74.67B66.12B59.76B
Total Debt
6.65B12.37B11.70B11.43B9.92B9.56B
Net Debt
-11.82B-9.61B-11.07B-12.45B-9.91B
Total Liabilities
30.90B43.91B41.91B41.03B34.79B31.55B
Stockholders Equity
24.18B35.90B34.92B32.07B29.06B26.14B
Cash FlowFree Cash Flow
4.73B2.31B2.48B5.62B4.42B
Operating Cash Flow
1.10B3.44B4.10B7.00B5.67B585.19M
Investing Cash Flow
-3.11B
Financing Cash Flow
1.03B-1.98B45.95M1.44B

Guangzhou Baiyunshan Pharmaceutical Holdings Company Technical Analysis

Technical Analysis Sentiment
Positive
Last Price18.04
Price Trends
50DMA
17.13
Positive
100DMA
17.44
Positive
200DMA
17.93
Positive
Market Momentum
MACD
0.21
Negative
RSI
66.26
Neutral
STOCH
96.30
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0874, the sentiment is Positive. The current price of 18.04 is above the 20-day moving average (MA) of 17.45, above the 50-day MA of 17.13, and above the 200-day MA of 17.93, indicating a bullish trend. The MACD of 0.21 indicates Negative momentum. The RSI at 66.26 is Neutral, neither overbought nor oversold. The STOCH value of 96.30 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0874.

Guangzhou Baiyunshan Pharmaceutical Holdings Company Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
76
Outperform
$101.88B22.1613.20%4.42%-9.60%-27.18%
75
Outperform
HK$80.35B11.8718.17%4.37%12.76%34.50%
74
Outperform
HK$32.93B11.9114.56%5.03%-5.37%6.28%
66
Neutral
$45.33B10.037.22%7.36%-4.07%-35.32%
66
Neutral
$81.38B42.886.14%1.32%7.63%-24.23%
62
Neutral
HK$33.61B9.25
3.02%
54
Neutral
$5.31B3.26-45.10%2.79%16.76%0.02%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:0874
Guangzhou Baiyunshan Pharmaceutical Holdings Company
18.04
-2.80
-13.41%
HK:1177
Sino Biopharmaceutical
4.74
2.05
75.95%
HK:3320
China Resources Pharmaceutical Group Ltd.
5.41
-0.17
-3.01%
HK:1513
Livzon Pharmaceutical Group
31.75
6.15
24.00%
HK:1093
CSPC Pharmaceutical Group
8.82
2.19
32.99%
HK:2313
Shenzhou International Group Holdings
54.35
-25.14
-31.63%

Guangzhou Baiyunshan Pharmaceutical Holdings Company Corporate Events

Guangzhou Baiyunshan Reports Decline in Q1 2025 Earnings
Apr 29, 2025

Guangzhou Baiyunshan Pharmaceutical Holdings Company reported a decrease in both income from operations and net profit for the first quarter of 2025 compared to the same period in 2024. The company experienced a 2.06% decline in income from operations and a 6.99% decrease in net profit attributable to shareholders. Additionally, the net cash flow from operating activities saw a significant drop of 24.19%. Despite these declines, the total equity attributable to shareholders increased by 5.05%, indicating a stronger financial position.

Guangzhou Baiyunshan’s Subsidiary Gains NEEQ Quotation Approval
Apr 29, 2025

Guangzhou Baiyunshan Pharmaceutical Holdings Company announced that its subsidiary, Guangzhou Pharmaceuticals Co., Ltd. (GP Corp.), has received approval for the public transfer and quotation of its shares on the National Equities Exchange and Quotations (NEEQ). This move allows GP Corp. to be governed as a non-listed public company while remaining a non-wholly owned subsidiary of Guangzhou Baiyunshan. The quotation on NEEQ will not significantly impact the financial position or operations of the parent company, maintaining its status as an independently listed entity.

Guangzhou Baiyunshan Subsidiary Receives Approval for Production License Changes
Apr 22, 2025

Guangzhou Baiyunshan Pharmaceutical Holdings Company announced that its subsidiary, Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd., received approval from the Guangdong Provincial Drug Administration for changes to its ‘Drug Production License’. The approval allows the subsidiary to reduce its production scope, workshops, and production lines, which could streamline operations and potentially impact its manufacturing efficiency and cost structure.

Guangzhou Baiyunshan to Review Q1 2025 Financial Results
Apr 15, 2025

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited has announced that its board of directors will meet on April 29, 2025, to review and approve the unaudited financial results for the first quarter of 2025. This meeting is significant as it provides insights into the company’s financial health and operational performance, which are crucial for stakeholders and investors monitoring the company’s market position and future prospects.

Guangzhou Baiyunshan Reports Strong 2024 Profits and Announces Dividend
Mar 13, 2025

Guangzhou Baiyunshan Pharmaceutical Holdings Company announced its 2024 annual report, highlighting a consolidated net profit of RMB 2.84 billion attributable to shareholders. The company proposed a cash dividend of RMB 0.40 per share, amounting to a total of RMB 650.32 million, with undistributed profits carried forward. This financial performance and profit distribution plan reflect the company’s stable position in the pharmaceutical industry and its commitment to rewarding shareholders.

Guangzhou Baiyunshan Announces Final Dividend for 2024
Mar 13, 2025

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited announced a final cash dividend of RMB 0.4 per share for the financial year ending December 31, 2024. This announcement reflects the company’s ongoing commitment to returning value to its shareholders, although specific details regarding the payment date and other related information are yet to be disclosed.

Guangzhou Baiyunshan Pharmaceutical to Review 2024 Financial Results
Feb 28, 2025

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited has scheduled a board meeting for March 13, 2025, to review and approve the audited financial results for the year ending December 31, 2024. This meeting will be crucial for stakeholders as it will provide insights into the company’s financial health and operational performance over the past year.

Guangzhou Baiyunshan’s GP Corp. Completes Significant Asset Disposal
Feb 28, 2025

Guangzhou Baiyunshan Pharmaceutical Holdings Company, through its subsidiary GP Corp., has engaged in a series of transactions involving the sale of accounts receivable to Industrial Securities Asset Management. The latest transaction, completed on February 28, 2025, involves the disposal of new underlying assets valued at RMB583,087,010.44. This transaction, when aggregated with previous similar transactions within a 12-month period, constitutes a disclosable transaction under Hong Kong’s Listing Rules, requiring reporting and announcement but not shareholder approval.

Guangzhou Baiyunshan Pharmaceutical Announces Director Resignation
Feb 14, 2025

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited announced the resignation of Mr. Wu Changhai from his roles as an executive director, a member of the Nomination and Remuneration Committee, and other positions within its subsidiaries due to work adjustments. His departure does not affect the statutory minimum number of board members or the board’s operations, and an election for a new director will be conducted following statutory procedures. The company expressed gratitude for Mr. Wu’s contributions during his tenure.

Guangzhou Baiyunshan Pharmaceutical Updates Board of Directors
Feb 14, 2025

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited has announced the list of its board of directors and their respective roles and functions. This update on the board structure may influence the company’s strategic direction and operational efficiency, affecting its positioning in the pharmaceutical industry.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.